The content on this site is intended for healthcare professionals only
Prof Salvatore Siena talks to ecancertv at the ESMO 14th World Congress on Gastrointestinal Cancer (WCGC) in Barcelona.
In the interview he discusses the concept of personalised medicine, one of the major themes of this year’s WCGC. He notes that advances have been made in understanding the possible mechanisms of resistance to molecularly-targeted therapies for colorectal cancer (CRC).
Prof Siena comments on some of the hot topics in CRC, such as the influence of Kras mutations on response to treatments such as cetuximab. He also notes that Kras mutations might be detectable in the peripheral blood.
Prof Siena also gives his personal views on next steps in the field of gastrointestinal (GI) oncology in relation to CRC.
This programme was supported by BAYER.
Post-diagnosis diet, nutrition and cancer prognosis
WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India
Alternative livelihood training programme for rural women who are employed in the tobacco industry in India
Selecting patients wisely for neoadjuvant therapy in HPB cancers
ESMO 2024: Highlights and analysis
Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Assessment of suicide risk in cancer patients
Cancer journeys: Research from India
